Cidara Therapeutics, Inc. is a biotechnology company headquartered in San Diego, California, focused on developing therapies for serious infectious diseases and other high-need conditions. The company’s work spans antifungal and antiviral modalities, with an emphasis on long‑acting, patient‑friendly dosing.
Cidara’s proprietary Cloudbreak platform generates drug–Fc conjugates (DFCs) that link targeted antiviral or other therapeutic agents to the Fc region of human antibodies to extend half‑life and engage immune mechanisms. Programs have included candidates aimed at prevention and treatment of respiratory viral infections and select immuno-oncology targets, advanced through internal R&D and collaborations.
Cidara originated rezafungin, a once‑weekly echinocandin antifungal for candidemia and invasive candidiasis, which has received regulatory approvals in the United States and Europe (marketed as Rezzayo) through commercial partners. The company operates primarily as a research and development organization, advancing its pipeline and partnering for late‑stage development and commercialization.
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
Strong oncology and animal health sales, positive trial results, and strategic acquisitions drive growth. 2026 outlook projects sales up to $67B, with EPS impacted by acquisition charges.
Merck acquires Cidara, enhancing its respiratory portfolio with CD388, a long-acting antiviral for influenza prevention, impacting 2026 R&D expenses and EPS.
Merck acquires Cidara for $9.2B, enhancing its pipeline with CD388, a late-phase antiviral for influenza prevention, pending regulatory approvals.
